Prelude Therapeutics Incorporated (PRLD)
PRLD Stock Price Chart
Explore Prelude Therapeutics Incorporated interactive price chart. Choose custom timeframes to analyze PRLD price movements and trends.
PRLD Company Profile
Discover essential business fundamentals and corporate details for Prelude Therapeutics Incorporated (PRLD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Sept 2020
Employees
131.00
Website
https://www.preludetx.comCEO
Krishna Vaddi
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
PRLD Financial Timeline
Browse a chronological timeline of Prelude Therapeutics Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.46.
Earnings released on 14 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.45 by +8.89%.
Earnings released on 6 May 2025
EPS came in at -$0.42 surpassing the estimated -$0.47 by +10.64%.
Earnings released on 10 Mar 2025
EPS came in at -$0.38 surpassing the estimated -$0.49 by +22.45%, while revenue for the quarter reached $4.00M .
Earnings released on 6 Nov 2024
EPS came in at -$0.43 surpassing the estimated -$0.48 by +10.42%, while revenue for the quarter reached $3.00M .
Earnings released on 12 Aug 2024
EPS came in at -$0.46 matching the estimated -$0.46.
Earnings released on 7 May 2024
EPS came in at -$0.42 surpassing the estimated -$0.47 by +10.64%.
Earnings released on 15 Feb 2024
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $3.42M .
Earnings released on 1 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.58 by +22.41%.
Earnings released on 3 Aug 2023
EPS came in at -$0.54 surpassing the estimated -$0.65 by +16.92%.
Earnings released on 8 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.68 by +14.71%.
Earnings released on 15 Mar 2023
EPS came in at -$0.60 surpassing the estimated -$0.63 by +4.76%.
Earnings released on 14 Nov 2022
EPS came in at -$0.63 matching the estimated -$0.63.
Earnings released on 9 Aug 2022
EPS came in at -$0.58 surpassing the estimated -$0.60 by +3.33%.
Earnings released on 10 May 2022
EPS came in at -$0.63 surpassing the estimated -$0.68 by +7.35%.
Earnings released on 16 Mar 2022
EPS came in at -$0.71 falling short of the estimated -$0.69 by -2.90%.
Earnings released on 12 Nov 2021
EPS came in at -$0.66 falling short of the estimated -$0.62 by -6.45%.
Earnings released on 12 Aug 2021
EPS came in at -$0.58 falling short of the estimated -$0.51 by -13.73%.
Earnings released on 11 May 2021
EPS came in at -$0.47 falling short of the estimated -$0.41 by -14.63%.
Earnings released on 16 Mar 2021
EPS came in at -$0.45 surpassing the estimated -$0.47 by +4.26%.
Earnings released on 10 Nov 2020
EPS came in at -$5.25 falling short of the estimated -$0.43 by -1.12K%.
Earnings released on 25 Sept 2020
EPS came in at -$0.29 .
PRLD Stock Performance
Access detailed PRLD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.